Condition
Advanced Esophageal Cancer
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Unknown3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03691090Phase 3CompletedPrimary
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
NCT05425472Phase 2UnknownPrimary
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
NCT05174156Phase 2UnknownPrimary
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
NCT03706326Phase 1UnknownPrimary
CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
Showing all 4 trials